|
|
|||||||
 |
|
|
LinkBack | Thread Tools | Display Modes |
08-21-2010, 02:37 AM
|
|||
|
|||
Additional Phase III Clinical Trial With Urocidin(TM) Expected To Commence In 2010
Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer Urocidin(TM). Bioniche and its development partner, Endo Pharmaceuticals Inc. (NASDAQ: ENDP), are in the process of finalizing a protocol for an additional clinical ...
    
|
|
| Thread Tools | |
| Display Modes | |
|
|
Similar Threads
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced pr | cancerfr | Oral Cancer | 0 | 09-30-2010 02:52 AM |
| Tengion Adds The Johns Hopkins Hospital As An Additional Clinical Trial Site For Its | cancerfr | Bladder Cancer | 0 | 09-11-2010 03:26 AM |
| Tengion Adds The Johns Hopkins Hospital as an Additional Clinical Trial Site For Its | cancerfr | Bladder Cancer | 0 | 09-10-2010 03:47 AM |
| Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic | cancerfr | Pancreatic Cancer | 0 | 07-21-2010 12:17 AM |
| Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010 | cancerfr | Stomach (Gastric) Cancer | 0 | 05-04-2010 02:41 PM |
Linear Mode
